Offices of Biotechnology and Business Development

Presentations, News & Publications

Future Events

*GSK funding collaborative opportunity - preproposal application due NO LATER than May 1st, 2014* 

*The Discovery Fast Track Challenge from the Discovery Partnerships with Academia (DPAc) group at GlaxoSmithKline (“GSK”) is announcing a call for proposals with the goal of discovering new pharmacologically active molecules via High Throughput Screening (HTS) and/or Encoded Library Technology (ELT).  For successful applicants, this will help drive their research forward and could lead to a partnership with GSK for the development of a new medicine.  

*Up to twenty projects, ten from Europe and ten from North America, will be selected in the 2014 challenge.  If you are interested in applying for this collaborative opportunity, a one-page non-confidential proposal should be submitted to Ece Auffarth, PhD (ece.auffarth@einstein.yu.edu) in the Office of Biotechnology, NO LATER than, May 1st , 2014  

*After review of your  non-confidential proposal, Dr. Auffarth will work with you in submitting your non-confidential proposal to the GSK portal. 


 

*Pfizer CTI funding collaborative opportunity - preproposal application due NO LATER than May 16th, 2014*  

Pfizer’s Centers for Therapeutic Innovation (“CTI”)  has announced its next call for proposals with the goal of selecting early-stage, large molecule projects related to inflammation, autoimmunity, tissue remodeling, oncology, rare or genetic diseases, neuroscience, cardiovascular and metabolic diseases  

CTI is especially seeking new partnerships in immunoregulation in autoimmune disease and cancer to either harness the immune system for tumor eradication or, conversely, targeted therapies to provide selective immunosuppression or immunoregulation for autoimmune diseases.  For cancer immunotherapy, this may involve mechanisms to target T regulatory cells, myeloid suppressor cells or other immune augmentation strategies.  For the treatment of autoimmune disease, CTI is interested in novel approaches to treat a variety of diseases associated with immune dysregulation, including proposals describing intervention points to drive the development of immunological tolerance and de novo generation and/or functional enhancement of T regulatory cells.   

Please submit a short, non-confidential pre-proposal to Ece Auffarth, PhD (ece.auffarth@einstein.yu.edu) in the Office of Biotechnology, NO LATER than  May 16th, 2014.  The Office of Biotechnology is looking forward to receiving your non-confidential proposal for this opportunity.  Please contact us at 718-430-3357  if you have any questions.   

 

 

Past Events 

 Patenting Novel Technologies: The Inside Story from the United States Patent and Trademark Office (USPTO) (May 13, 2013) 

Presented by: Sue Parvis, JD -- USPTO (Innovation and Outreach Coordinator)

 Pfizer's Center for Therapeutic Innovation (CTI) Program - 2nd Call for Proposals - oncampus workshop (October 3, 2012) 

Presented by: Jeanne Magram, Ph.D. -- Pfizer, Inc. (site head, Centers for Therapeutic Innovation - New York) & Bettina C. Fries, M.D. – Pfizer CTI Awardee; Albert Einstein College of Medicine (associate professor, department of medicine (infectious diseases) and department of microbiology & immunology)

Medical Innovation & Business: The Technology Commercialization Initiative at Montefiore (May 7, 2012)   

Co-sponsored with the Einstein-Montefiore Institute for Clinical & Translational Research

Presented by: Richard Kosman (director of Einstein’s office of business development) 

Science & Business: Commercial Catalysts in the Early-Stage Life Sciences Technology Ecosystem (May 5, 2011) 

Co-sponsored with the graduate division of biomedical sciences and the Belfer Institute for Advanced Biomedical Studies

Panelists included: (1) Elizabeth Stoner, M.D. (managing director, MPM Capital, and former senior vice president of Global Clinical Development Operations, Merck Research Laboratories;) (2) Ronald W. Lennox, D.Phil. (partner, CHL Medical Partners); (3) Milena Adamian, M.D. (director, Life Sciences Angel Network); (4) Melinda Thomas, M.B.A. (entrepreneur-in-residence for New York City, NYC Tech Connect)

Moderated by: Richard Kosman, Sc.M.M. (director, office of business development, Albert Einstein College of Medicine)

More information on this presentation can be found via the following links: "Commercial Catalysts in the Early-Stage Life Sciences Technology Ecosystem"

Science & Business: Investing in the Development of Einstein's Technologies (October 12, 2010) 

Co-sponsored with the department of medicine

Presented by: Richard Kosman (director of Einstein’s office of business development) and Dr. Victor L. Schuster (chair of Einstein’s department of medicine)

More information on this presentation can be found via the following links: "Introduction to Einstein's Technology Development Program and Its First Success Story" and "The Promise of Prostaglandin Transport"

Science & Business: A Journey from Harvard Square to Wall Street to Morris Park Ave... (February 17, 2010) 

Co-sponsored with the graduate division of biomedical sciences, the Belfer Institute for Advanced Biomedical Studies and the office of faculty development

Presented by: Richard Kosman (director of Einstein’s office of business development)

Licensing Einstein Technology: The Inside Story (September 24, 2009) 

Co-sponsored with the department of microbiology & immunology

Video from the seminar can be found online under "Lectures & Conferences".

Presented by: Remi Barbier (CEO of Pain Therapeutics, Inc.), Dr. Ekaterina Dadachova (representing the Einstein inventors [other co-inventors include Dr. Arturo Casadevall and Dr. Joshua Nosanchuk] and John Harb (assistant dean of scientific operations and director of Einstein's office of biotechnology)

Technology Transfer: An Alternative Career Path (May 6, 2009) 

Co-sponsored with the graduate division of biomedical sciences and the Belfer Institute for Advanced Biomedical Studies

Presented by: Dr. David Schoenhaut (assistant director of Einstein’s office of biotechnology), Dr. David Silva (senior business development analyst in Einstein’s office of business development), and Janis Peck (Business Development Analyst in Einstein’s office of business development)

Intellectual Property Overview for the Academic Researcher (December 9, 2008) 

Presented by: Kenneth P. George, Esq. (partner at Amster, Rothstein & Ebenstein LLP)

Introduction to the Offices of Biotechnology & Business Development (October 30, 2008) 

Presented by: John Harb (assistant dean of scientific operations and director of Einstein's office of biotechnology)

Einstein’s Director of Business Development, Richard Kosman, had the unique opportunity to share his extensive expertise in technology transfer with academics and authorities at two of the top universities in Chile.

Read more about his experience here: "Richard Kosman: Taking Technology Transfer Global"  

 

Chile-community     Chile-feedback1     Chile-feedback2  
Richard Kosman listens during a presentation to the university community       Richard Kosman leads a TTO team feedback session   

 

Novel funding collaborative opportunity  

*Pfizer’s Center for Therapeutic Innovation (“CTI”) and the Juvenile Diabetes Research Foundation (“JDRF”) together (“CTI-JDRF”) are announcing a call for proposals in the diabetes space with the goal of translating and accelerating novel, promising diabetes research from validated target to proof-of-mechanism in the clinic.  Specifically, CTI-JDRF is looking for early-stage, large-molecule projects related to diabetic nephropathy, immune tolerance and beta cell health.   

*Selected projects may receive up to $250,000 in funding per year for two years.  If you are interested in applying for this funding/collaborative opportunity, a non-confidential pre-proposal application must be submitted to Ece Auffarth, PhD (ece.auffarth@einstein.yu.edu) in the Office of Biotechnology NO LATER than Friday, February 14, 2014.

 

Patents issued to Einstein in 2010 

New Initiative from the Office of Business Development 

Introduction to Einstein's Technology Development Program and Its First Success Story 

Licensed Einstein Technologies Making News 

7/8/10 - More Promising Results from Dr. Vern Schramm’s Technology-- Clinical trials for gout using second-generation Immucillins 

Centers for Therapeutic Innovation (Collaboration with Pfizer)  

 
Click here to log in